文章：

头颈癌精准医疗研究进展

Progress in Precision Medicine for Head and Neck Cancer

原文发布日期：4 November 2024

DOI: 10.3390/cancers16213716

类型: Article

开放获取: 是

英文摘要：

This paper presents a comprehensive comparative analysis of biomarkers for head and neck cancer (HNC), a prevalent but molecularly diverse malignancy. We detail the roles of key proteins and genes in tumourigenesis and progression, emphasizing their diagnostic, prognostic, and therapeutic relevance. Our bioinformatic validation reveals crucial genes such as AURKA, HMGA2, MMP1, PLAU, and SERPINE1, along with microRNAs (miRNA), linked to HNC progression. OncomiRs, including hsa-miR-21-5p, hsa-miR-31-5p, hsa-miR-221-3p, hsa-miR-222-3p, hsa-miR-196a-5p, and hsa-miR-200c-3p, drive tumourigenesis, while tumour-suppressive miRNAs like hsa-miR-375 and hsa-miR-145-5p inhibit it. Notably, hsa-miR-155-3p correlates with survival outcomes in addition to the genes RAI14, S1PR5, OSBPL10, and METTL6, highlighting its prognostic potential. Future directions should focus on leveraging precision medicine, novel therapeutics, and AI integration to advance personalized treatment strategies to optimize patient outcomes in HNC care.

摘要翻译： 

本文对头颈癌这一常见但分子异质性显著的恶性肿瘤的生物标志物进行了全面比较分析。我们详细阐述了关键蛋白和基因在肿瘤发生发展中的作用，重点探讨其诊断、预后及治疗价值。通过生物信息学验证，我们发现了与头颈癌进展密切相关的关键基因（包括AURKA、HMGA2、MMP1、PLAU和SERPINE1）及微小RNA。其中促癌miRNA（如hsa-miR-21-5p、hsa-miR-31-5p、hsa-miR-221-3p、hsa-miR-222-3p、hsa-miR-196a-5p和hsa-miR-200c-3p）驱动肿瘤发生，而抑癌miRNA（如hsa-miR-375和hsa-miR-145-5p）则发挥抑制作用。值得注意的是，hsa-miR-155-3p与RAI14、S1PR5、OSBPL10、METTL6等基因共同显示出与生存结局的相关性，凸显其预后评估潜力。未来研究方向应聚焦于运用精准医学、新型治疗手段及人工智能技术，推动个体化治疗策略发展，以优化头颈癌患者的临床结局。

原文链接：

Progress in Precision Medicine for Head and Neck Cancer